Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OsrhCT and Dimethicone for Upper Endoscopy Visibility
NCT06722664Phase 2Active, not recruiting
- Sponsor
- Wuhan Healthgen Biotechnology Corp.
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Recombinant Human Chymotrypsin (3 arms), sponsored by Wuhan Healthgen Biotechnology Corp. Primary endpoint: Total Visibility Score at 3 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
Recombinant Human Chymotrypsin
Beyond the preview
Go deeper on NCT06722664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722664.